||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Motif Bio Share Discussion Threads
Showing 1101 to 1125 of 1125 messages
|I shall go along to the Motif Bio presentation at the Rocket Bar on Tuesday. Is anyone else planning to go along?
>>>>Vulgaris, could you give me a few (three ?) of what you consider the most important questions (criticisms) regarding Iclaprim to put to GL on Tuesday. TIA
Did anyone see this episode of "Trust me I'm a doctor" the other week, in particular the item starting at 36:20
Some researchers in the Netherlands are studing patients with Eczema associated with Staph Aureus and then attempting to reduce the Staph without hitting the other benign (beneficial bacteria). They hope to acheive this by using using endolysins (which do not cause resistance). They get the read out in around 12 months (according to the program), so I look forward to that.
A quick google search comes up with quite a few hits, for example this one, which I'm guessing was written by one of the sponsors:
|I have bought my first holding here today. This seems a useful informative board. The next 12 months look like they will be interesting. I am mainly in Immupharma (IMM) and there seems to be some familiar faces here too!|
|Second RNS out 20 mins ago.|
|luminoso, agree. Excellent to get trial recruited and dosed, just they have always said they will need more cash (as they failed to raise the original amount needed on Nasdaq).
Positive news today but needs to be seen in context.|
|It seems clear to me that they are saying they need to raise funds to complete Revive 2 and hope that headline results from Revive 1 will allow them to do so more easily. That could be another placing or a partnership or something else. I don't read the announcement as hinting any more than that.|
|I suspect that last sentence hints at likely partnerships/T.O. and the possibility that a simple fundraiser may not, therefore, be required. If trials go well, this is unlikely to remain independent IMO.|
|Really? This was from last week.
Financials – the company raised $25m before expenses in its NASDAQ IPO in November 2016. We expect that in 2016 Motif will have generated an operating loss for the year of $41m with SG&A costs of $4.3m and R&D expenses of $36.8m representing the vast majority of expenses and demonstrating the sharp focus on product development within the business. We estimate that Motif will have ended 2016 with cash of $23.6m but highlight that it is likely to have ended the year with accrued trial-related costs of around $10m. In 2017 we anticipate R&D spending will decrease as the company’s REVIVE-1 and REVIVE-2 ABSSSI phase III trials complete and assuming that the third phase III trial, INSPIRE (in bacterial pneumonia), will not commence in the absence of new funding. However, we believe that the likely positive REVIVE-1 results will enable access to new funding and this will allow both the completion of REVIVE-2 and the initiation of INSPIRE (estimated to cost around $40m over 3 years).|
|Above answers your question Waterloo, trial in Revive 2 ongoing, but the cash they raised last year ample funding!|
Comment: If this last patient was treated for only 5 days there will be a further maximum of 27 days until the final follow-up phone call is completed, taking us to the end of February for the trial to be concluded. Several weeks are ordinarily required for further data processing including unblinding and statistical analysis but the company is confident of being able to report headline results in Q2. As REVIVE-2 is still ongoing, we expect only headline safety and efficacy results from REVIVE-1 will be reported (too much detail could potentially compromise the blinding of REVIVE-2). We remain confident of a positive outcome for the study based on prior efficacy and safety data obtained using iclaprim in earlier phase III trials.|
|A little confused as I thought they stated they needed to raise funds to complete the Revive 2 trial? Is that not now the case?
They said this in November placing:
While the Board believes that, along with the Company's existing cash and cash equivalents, the net proceeds of the Fundraising will provide sufficient capital to enable the Company to complete the REVIVE-1 trial, the Company will require additional funds to complete the REVIVE-2 trial and plans to raise the additional capital through public or private financings and/or other partnering opportunities.|
|So . Trials completed. Will There be an anticipatory rise into results?|
|Appears they have completed P111 trials, and data read out will be avaliable starting 2Q 17, as per stated late 2016!|
|I'd suggest a good deal higher, irrespective of the placing they have fallen considerably, a retrace of a little it would justifiable, after all they considerably strengthened the balance sheet!|
|Shares in Motif Bio could rally to 35p says Zak Mir
|Interview with Zeus Capital - Dr Gary Waanders
|Nice little rise today, I'd just love to see it do a 10/20% uplift!|
|There's a bit more talk on twitter about this share|
|yes ive seen it before.still, atleast someones got it reprinted to try and kick the price .last time it didn't seem to have any effect.maybe they thought itd work better now some of the placing stocck has gone.gl|
Old I think but has today's date?|
|MTFB closed up 4.8% on Nasdaq last night.|
|Well done WaterlooPrefer this to summ|
|I note Motif are presenting here. I've added of late.
12:25 Panel III – Anti Bacterial/microbiome
Moderator: Sarah Haywood, CEO, MedCity
• Richard Mason, Head of J&J Innovation, London, J&J
• Graham Lumsden, CEO, Motif Bio
• Neil Murray, CEO, Redx
• Glyn Edwards, CEO, Summit
|The MTFB ADS's up over 6% on Nasdaq. Beginning to look good on both sides of the Atlantic!|
|That's a very bullish forecast from Zeus on the Voxmarket podcast
Zeus risk adjusted target is now 107p/share
There's another interview with Garry Waanders that appeared this morning on Directors talk: